Startups
EPISEEK® is a simple blood test that screens for 60+ cancer types using advanced DNA methylation analysis. CAP-accredited, CLIA-certified lab.
Overview
Total raised
$1.5M
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 5, 2026 | University of Arizona Leads Landmark Clinical Study Evaluating EPISEEK Pleural Fluid Liquid Biopsy Cancer Test | University of Arizona Pulmonary Division Leads Landmark Clinical Study Evaluating Precision Epigenomics’ Pleural Fluid (EPISEEK-MPE) Cancer Detection Test Evaluating this technology in real-world clinical settings will help determine how mo... |
| Feb 3, 2026 | Precision Epigenomics Receives CAP Accreditation, Advancing Commitment to Quality and Clinical Excellence | Achieving CAP accreditation is a significant milestone for Precision Epigenomics” — Joshua Routh, MD, Medical Director of Precision Epigenomics TUCSON, AZ, UNITED STATES, February 3, 2026 /EINPresswire.com/ -- Precision Epigenomics today an... |
| Oct 3, 2025 | EPISEEK Detects Stages I-IV Pancreatic Cancer with Minimal Sample Volume | Precision Epigenomics presents the latest EPISEEK Multi-Cancer Early Detection (MCED) test performance data at AACR Conference this week. Highly lethal malignancies like pancreatic cancer are often diagnosed at a very late stage, when resec... |
| Nov 22, 2024 | Precision Epigenomics Shares Abstracts Showing Performance of Assays for Melanoma and Brain Cancer Detection | Precision Epigenomics Precision Epigenomics announced that the company presented data supporting the critical role of its melanoma classifier. Brain cancer has a very aggressive course, so we are pleased that the EPISEEK blood test has show... |
| Sep 11, 2024 | Precision Epigenomics Announces Closing of $1.5M Series A1 Funding | The EPISEEK™ multi-cancer detection test is now available with a Healthcare Provider's order. With this funding, Precision Epigenomics has raised more than $3.9M in investments helping move the company into the revenue stage. This test is t... |
| Aug 30, 2024 | A New Dawn in Autoimmune and Cancer Detection: NIH Grants Propel Innovation | In the realm of medical innovation, funding is the lifeblood that fuels discovery. Recently, two biopharmaceutical companies received significant grants from the National Institutes of Health (NIH), marking a pivotal moment in the fight aga... |
| Aug 29, 2024 | Precision Epigenomics Receives $2M Award from National Institutes of Health | Precision Epigenomics (PRNewsfoto/Precision Epigenomics) This award will lead to the development of EPISEEK-MPE, a multi-cancer detection test, using pleural fluid to detect cancer. TUCSON, Ariz., Aug. 29, 2024 /PRNewswire-PRWeb/ -- Precisi... |
| Precision Epigenomics | “Precision Epigenomics |” |
Reviews 0
FAQ about EPISEEK® Multi
How much funding has EPISEEK® Multi raised?
EPISEEK® Multi has raised $1.5M in total across 1 funding round.
What has the press written about EPISEEK® Multi?
Parsers VC has collected 9 articles mentioning EPISEEK® Multi, among them “University of Arizona Leads Landmark Clinical Study Evaluating EPISEEK Pleural Fluid Liquid Biopsy Cancer Test” (May 5, 2026) and “Precision Epigenomics Receives CAP Accreditation, Advancing Commitment to Quality and Clinical Excellence” (Feb 3, 2026).
Is EPISEEK® Multi still active?
EPISEEK® Multi is probably closed: its latest activity on Parsers VC dates from Sep 21, 2026.